|
| Tuesday, 22 June 2021, 09:30 HKT/SGT | |
| |  | |
Source: Fujitsu Ltd | |
|
|
|
|
| Exploration into molecular mechanisms of infection inhibition may lead to development of new COVID-19 Treatments |
TOKYO, June 22, 2021 - (JCN Newswire) - Fujitsu Japan Limited today announced that it will initiate a new research project with a research team led by Takefumi Yamashita, Project Associate Professor of Research Center for Advanced Science and Technology (RCAST) , the University of Tokyo utilizing the world's fastest supercomputer, Fugaku, which was jointly developed by RIKEN and Fujitsu. The research will leverage Fugaku to identify small molecule inhibitory compounds that can be used as potential drugs in treatments for COVID-19 as well as clarifying the molecular mechanism by which COVID-19 infections are inhibited, leading to the eventual development of small molecule therapeutic drugs. Full scale research begins on June 22nd, 2021 and will continue until March of 2022.
 | | Fig.1 Docking simulation of viral protein and inhibitory compound |
 | | Fig. 2 Molecular Dynamics Simulations of Viral Proteins and Inhibitory Compounds |
 | | Fig. 3 Property prediction of mutant strains |
In their joint research, Fujitsu and RCAST will leverage IT drug discovery technology with a focus on inhibitory compound creation technology and molecular simulation technology that precisely represents the state of molecules, performing calculations on Fugaku to identify inhibitory compounds based on the dynamic behavior of viral proteins and to predict the properties of future mutations. By utilizing Fugaku, molecular simulations for viral proteins and inhibitory compounds formulation can be accelerated, clarifying the complexity of binding states and interactions between viral proteins and inhibitory compounds, with the aim of identifying inhibitory compounds that can lead to therapeutic drugs at an early stage.
Going forward, Fujitsu will continue harnessing the power of supercomputers and molecular simulation technologies as it strives to quickly deliver on the promise of potential therapies for COVID-19 with its joint research alongside RCAST Project Associate Professor Yamashita, contributing to the realization of a society in which all people can live with peace of mind.
Background
Since 2011, Fujitsu has been engaged in joint research with RCAST on IT drug discovery technologies to create candidate small molecule compounds for anticancer drugs and other therapies. While a number of highly effective vaccines have been successfully developed in response to the spread of the COVID-19 pandemic, the development of effective therapeutic drugs remains an important priority. Based on the fruits of their joint research to date in the field of IT drug discovery technology, Fujitsu and RCAST have decided to embark on a new intensive research project to identify inhibitory compounds that will lead to the development of new coronavirus drugs, leveraging the unparalleled computing power of Fugaku to contribute to this goal.
Overview of the Joint Research
Since 2011, Fujitsu and RCAST have been conducting joint research on small molecule drugs that are highly likely to be taken orally, are chemically synthesizable, and have low production costs compared to drugs in forms of peptide drugs, antibody drugs, nucleic acid drugs, and cell drugs. With the goal of identifying inhibitory compounds that lead to develop new coronavirus drugs that are effective in small doses and reduce the risk of side effects, molecular simulation technology that is the result of the joint research will be utilized. As it is vital to create a molecular structure that can bind strongly to the viral protein and control its activity, molecular simulation technology and Fugaku will be widely used for tasks including the creation of three-dimensional structural models, clarifying the molecular mechanisms of infection inhibition, and predicting the properties of mutant strains.
1. Clarification of the molecular mechanism of infection inhibition leading to the development of therapeutic drugs.
Produce a three-dimensional structure model of viral protein and candidate compound for an infection-inhibiting molecular structure.
After searching for candidate regions where molecules can bind to viral proteins derived from a coronavirus, for each candidate region, docking simulation(1) is used to search for the positions and orientations of inhibitory compounds. The candidate state in which the viral proteins and inhibitory compounds bind is derived to generate a three-dimensional structural model.
Track dynamic behavior of viral protein and inhibitory molecular compound based on generated three-dimensional structure model, verify effect in the body.
In order to confirm that a viral protein and an inhibitory compound can exist stably in a state where they are bound even in an environment close to physiological conditions in the body, their dynamic behavior in a three-dimensional structure model is evaluated with a molecular dynamics simulation(2). Based on the microscopic images at the molecular level obtained from these simulations, the molecular mechanism of infection inhibition will be clarified with academic advice from RCAST Project Associate Professor Yamashita, and knowledge on the interaction between viral proteins and inhibitory compounds will be obtained.
Based on the findings obtained here, Fujitsu will identify information that offering the potential for improvements in the molecular structure of drugs and optimizing molecular structure in order to rapidly develop new small molecule drugs.
2. Running simulations to predict behavior and properties of mutant strains in order to make effective therapeutics for future viral mutations.
Property prediction of mutations will be carried out with the aim of establishing a process that can quickly lead to the development of a specific drug for mutant strains of the virus by predicting their properties, including for new types of coronaviruses, using simulations.
By mutating the amino acid sequence of a viral protein and simulating its behavior with Fugaku, it becomes possible to predict how mutations can affect the structure and function of viral proteins, as well as the manner in which they might interact with inhibitory compounds.
(1) Docking Simulation:
Technique for predicting the structure of a complex of a protein and a small molecule that may bind to it.
(2) Molecular Dynamics Simulation:
Technology that calculates the amount of energy and changes in the shape of a substance by calculating the forces between atoms that make up a molecule over time. Because the computational complexity increases exponentially with the number of atoms, a large supercomputer is needed to handle proteins and other high-molecular-weight materials in a precise manner that takes into account the living environment.
Fujitsu's Commitment to the Sustainable Development Goals (SDGs)
The Sustainable Development Goals (SDGs) adopted by the United Nations in 2015 represent a set of common goals to be achieved worldwide by 2030. Fujitsu's purpose -- "to make the world more sustainable by building trust in society through innovation"--is a promise to contribute to the vision of a better future empowered by the SDGs.
About Fujitsu
Fujitsu is the leading Japanese information and communication technology (ICT) company offering a full range of technology products, solutions and services. Approximately 126,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$34 billion) for the fiscal year ended March 31, 2021. For more information, please see www.fujitsu.com.
Topic: Press release summary
Source: Fujitsu Ltd
Sectors: Enterprise IT, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Fujitsu Ltd |
| Feb 6, 2026 10:14 HKT/SGT |
|
Fujitsu Japan and JMDC announce collaboration to build sustainable healthcare system in Japan through enhanced medical data utilization |
| Feb 6, 2026 09:44 HKT/SGT |
|
Genesys and Fujitsu Transform AEON Financial Service's Contact Center Operations with Genesys Cloud Delivers Customers an Improved Self-Service Experience Resulting in Higher Completion and Reduced Wait Times |
| Feb 3, 2026 10:14 HKT/SGT |
|
Fujitsu's Takane LLM successfully piloted in central government agency to streamline public comment operations |
| Feb 2, 2026 15:29 HKT/SGT |
|
Lockheed Martin and Fujitsu to accelerate dual-use technology development |
| Feb 2, 2026 13:30 HKT/SGT |
|
Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading |
| Jan 28, 2026 09:55 HKT/SGT |
|
Fujitsu and Tokai National Higher Education and Research System develop space weather prediction capabilities technology leveraging AI |
| Jan 26, 2026 12:30 HKT/SGT |
|
Fujitsu launches new platform enabling autonomous operation of generative AI optimized for in-house applications in a dedicated environment |
| Jan 26, 2026 09:45 HKT/SGT |
|
Fujitsu to support Mizuho Financial Group's human capital disclosure with a non-financial information collection and disclosure support service |
| Jan 22, 2026 10:30 HKT/SGT |
|
Fujitsu and Mizuho Bank partner to develop new order and payment processing service for SMEs |
| Jan 20, 2026 10:23 HKT/SGT |
|
Fujitsu recognized by World Economic Forum for project promoting sustainable hospital management leveraging AI |
| More news >> |
 |
|
|
|
